432
Views
7
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure

, , , , , & show all
Pages 2271-2276 | Received 29 Oct 2013, Accepted 16 Jan 2014, Published online: 17 Mar 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Shaji K. Kumar & Morie A. Gertz. (2014) Risk adapted therapy for multiple myeloma: back to basics. Leukemia & Lymphoma 55:10, pages 2219-2220.
Read now

Articles from other publishers (6)

Haotian Shi, Wei Wei, Rong Peng, Haimin Chen, Nian Zhou, Lixia Wu, Wenjun Yu, Wenhao Zhao, Jian Hou & Fan Zhou. (2023) Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications. Frontiers in Oncology 13.
Crossref
Cem Simsek, Ece Esin & Suayib Yalcin. (2019) Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience. Journal of Oncology 2019, pages 1-31.
Crossref
Andreas Pircher, Normann Steiner & Eberhard Gunsilius. 2019. Tumor Angiogenesis. Tumor Angiogenesis 327 347 .
Durga Prasanna Misra & Sajjan N. Shenoy. (2016) Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk. Rheumatology International 37:1, pages 151-167.
Crossref
Andreas Pircher, Normann Steiner & Eberhard Gunsilius. 2017. Tumor Angiogenesis. Tumor Angiogenesis 1 22 .
Yuliya Snihur, Eddy Pasquier, Graciela Scharovsky & Nicolas Andre. 2014. Metronomic Chemotherapy. Metronomic Chemotherapy 247 261 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.